# Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM

Study · id `cardio:ct-nct02467920` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02467920](<https://clinicaltrials.gov/study/NCT02467920>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02467920

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 349 participants.

## Technical summary

Registry record NCT02467920. Randomized; no masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2017-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 349 participants (enrolled count; ClinicalTrials.gov record NCT02467920, source copy `cardio:ctgov-nct02467920-2018-11-14`, retrieved 2026-10-26)
- Started: 2015-08 (actual) (ClinicalTrials.gov record NCT02467920, source copy `cardio:ctgov-nct02467920-2018-11-14`, retrieved 2026-10-26)
- Primary completion: 2017-12 (actual) (ClinicalTrials.gov record NCT02467920, source copy `cardio:ctgov-nct02467920-2018-11-14`, retrieved 2026-10-26)
- Completion: 2017-12 (actual) (ClinicalTrials.gov record NCT02467920, source copy `cardio:ctgov-nct02467920-2018-11-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02467920, source copy `cardio:ctgov-nct02467920-2018-11-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02467920-2018-11-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): glargine + exenatide
- Intervention (Drug): aspart 30
- Lead sponsor: Huazhong University of Science and Technology
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Huazhong University of Science and Technology (`cardio:org-huazhong-university-of-science-and-technology`)

## Provenance

Content hash: 4fff259036b6ff561c0812821ab7f6eabf908efd4a43b12e121b4b73af2fed52
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
